Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-17 blocking antibody
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
An IL-17 blocking antibody is a monoclonal antibody designed to target and neutralize interleukin-17 (IL-17), a pro-inflammatory cytokine primarily produced by T-helper 17 (Th17) cells. By binding to IL-17 (such as IL-17A or IL-17F) or its receptor (IL-17R), these antibodies inhibit downstream signaling pathways that drive inflammation, tissue remodeling, and autoimmune pathology. IL-17 blocking antibodies are widely used or investigated for the treatment of various autoimmune and inflammatory conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and potentially other diseases like primary sclerosing cholangitis (PSC) and rheumatoid arthritis.
02
Targets
IL-17A (Interleukin-17A)IL17F (Interleukin 17F)
Beyond the preview
Go deeper on IL-17 blocking antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-17 blocking antibody.